Clinical trials: TACE
Hepatocellular Carcinoma
Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs
The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.
- Trial name
- NCT00357474
- Testing
- Transarterial chemoembolization, Percutaneous ethanol injection therapy
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT).
- Trial name
- NCT02221778
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- University of Sao Paulo
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma
Hypothesis: Patients with hepatocellular carcinoma (HCC) have few options if they fail or are unable to undertake surgery, transarterial chemoembolization (TACE) and/or chemotherapy.
- Trial name
- TACERT (NCT03079778)
- Testing
- transarterial chemoembolization, TACE plus RT
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatocellular Carcinoma
Follow up After TACE by Elastography and Color Doppler.
To determine accuracy of elastography and color Doppler in follow up of patients with HCC after TACE comparing with modified RECIST criteria.
- Trial name
- NCT06070623
- Testing
- US
- Volunteers
- 54 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
The objective of this study is to evaluate the efficacy and safety of TACE combined with Sintilimab plus bevacizumab biosimilar in patients with advanced hepatocellular carcinoma as first-line therapy.
- Trial name
- NCT04954794
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
- Trial name
- TACE-3 (NCT04268888)
- Testing
- Nivolumab and TACE/TAE, TACE/TAE
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 522 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Hepatocellular Carcinoma
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
This study used (cTACE or DEB-TACE + FOLFOX scheme HAIC) combined with PD-1 antibody camrelizumab and apatinib mesylas in the treatment of patients with advanced liver cancer, to evaluate the effectiveness and safety of the…
- Trial name
- NCT04479527
- Testing
- Camrelizumab
- Volunteers
- 34 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Hepatocellular, Survival Rate
Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor
This clinical trial aims to compare hepatectomy with Transarterial Chemoembolization (TACE) for Hepatic Cellular Cancer With Solitary Huge Tumor (≥5cm).
- Trial name
- NCT03191123
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma, Adjuvant
Adjuvant TACE in HCC With High-risk Recurrence Factors
The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended…
- Conditions
- Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization
- Trial name
- NCT07417397
- Testing
- Adjuvant transarterial chemoembolization, Intensive follow-up
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Guangxi Medical University
Intrahepatic Cholangiocarcinoma
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional…
- Trial name
- NCT05247996
- Testing
- Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint Inhibitor Therapy
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Hepatocellular Carcinoma (HCC)
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with…
- Trial name
- NCT07075562
- Testing
- Bevacizumab Arterial Perfusion plus TACE, Conventional Therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Hospital of Hebei Medical University